Tirzepatide vs Retatrutide: Dual vs Triple Receptor Agonism
Tirzepatide is FDA-approved GIP+GLP-1 dual agonism (~21% weight loss). Retatrutide is GLP-1+GIP+glucagon triple agonism in Phase 3 (~24% Phase 2). Here's how they compare.
Published Jun 14, 20265 min read
Tirzepatide (Mounjaro / Zepbound) is FDA-approved GIP+GLP-1 dual receptor agonism — the current best-in-class on label with ~21% mean weight loss in Phase 3. Retatrutide adds glucagon-receptor agonism on top, making it a GLP-1 + GIP + glucagon triple agonist. Phase 2 produced ~24% mean weight loss — larger than any other weight-loss drug in modern trials. Phase 3 in progress. This article covers the side-by-side: mechanism, evidence, what we know, and what we don't.
For the broader landscape, see peptides for weight loss and best peptides for fat loss.
Quick verdict table
| Tirzepatide | Retatrutide | |
|---|---|---|
| Brand name | Mounjaro (T2D), Zepbound (obesity) | Not yet — Phase 3 |
| Mechanism | GIP + GLP-1 dual agonist | GLP-1 + GIP + glucagon triple agonist |
| Approval | FDA-approved 2022 (T2D), 2023 (obesity) | Phase 3 (TRIUMPH program); FDA submission targeted late 2026 / early 2027 |
| Trial weight loss (best read) | ~21% at 72 weeks (SURMOUNT-1) | ~24% at 48 weeks (Phase 2, NEJM 2023) |
| Dose schedule | Weekly SC | Weekly SC |
| CV outcome data | SURPASS-CVOT reads 2026–2027 | Long-term Phase 3 CV trial ongoing |
| Available now? | Yes | No |
Mechanism
Tirzepatide
Binds and activates two receptors:
- GLP-1 receptor — appetite suppression, slowed gastric emptying, glucose-dependent insulin release.
- GIP receptor — modulates insulin response, lipid handling.
The combination is empirically synergistic — GIP alone in trials does not reliably produce weight loss, but added to GLP-1 it amplifies the effect.
Retatrutide
Adds a third axis on top of Tirzepatide's two:
- GLP-1 receptor — same as Tirzepatide.
- GIP receptor — same as Tirzepatide.
- Glucagon receptor — adds increased energy expenditure (the body burns more calories at rest).
The glucagon-receptor component is the engineering trick. Pure glucagon agonism would raise blood glucose (it's the hormone that releases glucose from the liver). But the simultaneous GLP-1 agonism overrides the glucagon-driven hyperglycemia, leaving the energy-expenditure benefit without the glucose downside.
Trial data
Tirzepatide — SURMOUNT-1
2,539 adults with obesity but without T2D, randomized to Tirzepatide 5 mg, 10 mg, 15 mg weekly, or placebo. At 72 weeks at the 15 mg dose:
- Mean weight loss: ~21%.
- ~57% of patients lost ≥20% of body weight.
- ~36% lost ≥25%.
For full T2D and head-to-head-vs-Semaglutide data, see Semaglutide vs Tirzepatide.
Retatrutide — Phase 2 NEJM 2023
338 adults with obesity (with and without T2D), randomized to multiple Retatrutide doses or placebo. At 48 weeks at the 12 mg dose:
- Mean weight loss: ~24%.
- ~26% of patients lost ≥25% of body weight.
For context: Retatrutide's 48-week number exceeds Tirzepatide's 72-week number. The mechanistic claim — adding glucagon agonism on top of dual-receptor activation — appears to deliver as advertised in Phase 2.
Phase 3 (TRIUMPH program) is the test of whether the Phase 2 effect size holds up at scale and across longer trial durations.
Side effects
Tirzepatide — well-characterized at scale post-approval:
- Common: Nausea (~25–40% in trials), vomiting (5–25%), diarrhea (15–25%), constipation (5–15%).
- Most GI side effects are dose-related and improve with titration.
- Boxed warning: Thyroid C-cell tumor risk (rodent finding).
- Less common: pancreatitis, gallbladder disease, hair shedding, muscle-mass loss alongside fat loss.
Retatrutide — Phase 2 profile broadly similar to Tirzepatide with two differences:
- Slightly higher GI symptom rates at the highest dose (consistent with the larger effect).
- Slight heart-rate elevation (a few bpm on average) — consistent with the glucagon-driven energy-expenditure mechanism.
- Small increases in fasting glucose in non-diabetic patients (consistent with glucagon agonism); does not translate to clinically meaningful hyperglycemia.
Phase 3 will clarify the tolerability picture at population scale.
What's known vs not known
Known about Retatrutide
- Mechanism works in humans (Phase 2 demonstrates the effect).
- Side-effect profile in Phase 2 is broadly similar to other GLP-1-class drugs.
- The glucagon-driven energy-expenditure increase is measurable.
Not yet known
- Whether the Phase 2 effect size holds at Phase 3 scale. Phase 2 results often shrink modestly in Phase 3; whether 24% becomes 20% or holds at 24% matters clinically and commercially.
- Long-term cardiovascular outcomes. Both Semaglutide (SELECT) and Tirzepatide (SURPASS-CVOT pending) data points are absent for Retatrutide. The CV trial reads later.
- Chronic safety of glucagon-receptor agonism in humans. Multi-year exposure data does not exist.
- Real-world supply. Tirzepatide had material supply constraints in 2022–2024; Retatrutide could repeat that pattern.
- Cost and access. Pricing is not announced; market expectations are in line with or above Tirzepatide.
How to think about choosing today
For someone making a decision in mid-2026:
- You need treatment now? Tirzepatide is the largest-effect approved drug. Start there.
- You're considering waiting for Retatrutide? The clinical timeline is 2027 at earliest. Waiting means foregoing 12+ months of treatment effect.
- You're on Tirzepatide and plateauing? Stay on Tirzepatide; CagriSema and Retatrutide are the future Phase 3 contenders to consider switching to once approved.
- You're in a Retatrutide clinical trial site's catchment area? Trial enrollment is the legitimate path to Retatrutide today.
Off-label access via research-chemical channels carries the usual product-quality and dosing risk — see are peptides safe?.
Where it sits relative to other future contenders
| Mechanism | Phase | Best trial weight loss | |
|---|---|---|---|
| Semaglutide | GLP-1 | Approved | ~15% |
| Tirzepatide | GIP + GLP-1 | Approved | ~21% |
| CagriSema | Amylin + GLP-1 | Phase 3 | ~22% (REDEFINE-1) |
| Survodutide | GLP-1 + glucagon | Phase 3 | ~19% (Phase 2) |
| Mazdutide | GLP-1 + glucagon | Phase 3 (China) | ~15% |
| Orforglipron | Oral GLP-1 (small molecule) | Phase 3 | ~14% |
| Retatrutide | GLP-1 + GIP + glucagon | Phase 3 | ~24% (Phase 2) |
Retatrutide has the largest published Phase 2 effect size; CagriSema is the closest published Phase 3 number; Tirzepatide is the largest among currently-approved drugs.
Where to go from here
- Per-peptide profiles: Tirzepatide, Retatrutide, Semaglutide, Cagrilintide.
- Peptides for weight loss — the broader pillar.
- Semaglutide vs Tirzepatide — adjacent comparison.
- Best peptides for fat loss — full ranked roundup.
- Retatrutide explained, Cagrilintide explained — deeper single-drug explainers.
- Are peptides safe?, peptide side effects, peptide therapy — safety + clinical frame.
This is informational, not medical advice. Retatrutide is not FDA-approved.